Brokerages remain selectively bullish on stocks with strong earnings visibility and structural growth drivers despite recent volatility in the broader market. According to reports from The Economic Times, the latest recommendations from Anand Rathi and Equirus Securities highlight opportunities in companies that are well-positioned to benefit from capacity expansion, market share gains and improving operating leverage. The recommendations span across multiple sectors including healthcare, banking, defence, pharmaceuticals and specialty chemicals, all backed by improving earnings prospects and strong business fundamentals.
Anand Rathi has maintained a 'Buy' rating on Jubilant Ingrevia with a target price of ₹980, suggesting a potential upside of 35% from the current market price of ₹725. This represents a significant upgrade from previous recommendations, reflecting the brokerage's confidence in the company's growth prospects across the healthcare sector.
Anand Rathi maintained a 'Buy' rating on Bansal Wire Industries with a target price of ₹380, citing strong execution capabilities. As reported by The Economic Times, the brokerage's positive outlook is based on the company's demonstrated ability to execute its business strategy effectively.
Equirus Securities kept a 'Buy' rating on Greenply Industries with a target price of ₹391, driven by expectations of volume growth. According to The Economic Times, the brokerage's recommendation is supported by the company's anticipated improvement in sales volumes, which could drive future performance.
Pharmaceutical sector funds have delivered exceptional returns, with pharma funds generating an average return of 12.57% in the last three months and 20.22% over the past six months, outperforming every other domestic mutual fund category as well as international funds during these periods. According to latest category performance data, the sector has maintained its leadership in the current calendar year, generating an average return of 13.94%, making it the top-performing domestic mutual fund segment so far. However, experts caution that much of the re-rating has already occurred, with future performance likely to depend more on earnings growth than further valuation expansion. As per Rajesh Minocha, a Certified Financial Planner, the sector continues to benefit from improved earnings visibility, reduced pricing pressure in the US generics market, strong domestic demand, and renewed investor interest in defensive sectors.
